{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:47:03Z","timestamp":1726188423753},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,12]]},"DOI":"10.7759\/cureus.69286","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T22:28:19Z","timestamp":1726180099000},"source":"Crossref","is-referenced-by-count":0,"title":["Left Atrial Appendage Closure: A Single-Center Experience in a Population With a High Prevalence of End-Stage Renal Disease"],"prefix":"10.7759","author":[{"given":"Luis A","family":"Areiza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan F","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1453","article-title":"Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study","volume":"361","author":"Staerk L","year":"2018","unstructured":"Staerk L, Wang B, Preis SR, et al.. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018, 361:k1453. 10.1136\/bmj.k1453","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab648","article-title":"Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al.. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021, 42:4194. 10.1093\/eurheartj\/ehab648","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis","volume":"3","author":"Randhawa MS","year":"2020","unstructured":"Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Netw Open. 2020, 3:e202175. 10.1001\/jamanetworkopen.2020.2175","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear JL","year":"1996","unstructured":"Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996, 61:755-759. 10.1016\/0003-4975(95)00887-X","journal-title":"Ann Thorac Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.08.016","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial","volume":"2","author":"Montalescot G","year":"2009","unstructured":"Montalescot G, Gallo R, White HD, et al.. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009, 2:1083-1091. 10.1016\/j.jcin.2009.08.016","journal-title":"JACC Cardiovasc Interv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv730","article-title":"Implant success and safety of left atrial appendage closure with the Watchman device: peri-procedural outcomes from the EWOLUTION registry","volume":"37","author":"Boersma LV","year":"2016","unstructured":"Boersma LV, Schmidt B, Betts TR, et al.. Implant success and safety of left atrial appendage closure with the Watchman device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016, 37:2465-2474. 10.1093\/eurheartj\/ehv730","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"Holmes DR Jr","year":"2015","unstructured":"Holmes DR Jr, Doshi SK, Kar S, et al.. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015, 65:2614-2623. 10.1016\/j.jacc.2015.04.025","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes DR","year":"2009","unstructured":"Holmes DR, Reddy VY, Turi ZG, et al.. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009, 374:534-542. 10.1016\/S0140-6736(09)61343-X","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes","volume":"138","author":"Dukkipati SR","year":"2018","unstructured":"Dukkipati SR, Kar S, Holmes DR, et al.. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018, 138:874-885. 10.1161\/CIRCULATIONAHA.118.035090","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug","volume":"11","author":"Tzikas A","year":"2016","unstructured":"Tzikas A, Shakir S, Gafoor S, et al.. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016, 11:1170-1179. 10.4244\/EIJY15M01_06","journal-title":"EuroIntervention"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2014.08.009","article-title":"The left atrial appendage: anatomy, function, and noninvasive evaluation","volume":"7","author":"Beigel R","year":"2014","unstructured":"Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014, 7:1251-1265. 10.1016\/j.jcmg.2014.08.009","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.12.040","article-title":"The NCDR left atrial appendage occlusion Registry","volume":"75","author":"Freeman JV","year":"2020","unstructured":"Freeman JV, Varosy P, Price MJ, et al.. The NCDR left atrial appendage occlusion Registry. J Am Coll Cardiol. 2020, 75:1503-1518. 10.1016\/j.jacc.2019.12.040","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.010","article-title":"Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation","volume":"69","author":"Reddy VY","year":"2017","unstructured":"Reddy VY, Gibson DN, Kar S, et al.. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2017, 69:253-261. 10.1016\/j.jacc.2016.10.010","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26903","article-title":"Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet","volume":"90","author":"Lempereur M","year":"2017","unstructured":"Lempereur M, Aminian A, Freixa X, et al.. Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv. 2017, 90:E111-E121. 10.1002\/ccd.26903","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2014.03.003","article-title":"Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model","volume":"7","author":"Kar S","year":"2014","unstructured":"Kar S, Hou D, Jones R, et al.. Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model. JACC Cardiovasc Interv. 2014, 7:801-809. 10.1016\/j.jcin.2014.03.003","journal-title":"JACC Cardiovasc Interv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.03.253","article-title":"Changes in coagulation and platelet activation markers following transcatheter left atrial appendage closure","volume":"120","author":"Rod\u00e9s-Cabau J","year":"2017","unstructured":"Rod\u00e9s-Cabau J, O'Hara G, Paradis JM, et al.. Changes in coagulation and platelet activation markers following transcatheter left atrial appendage closure. Am J Cardiol. 2017, 120:87-91. 10.1016\/j.amjcard.2017.03.253","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-22-00627","article-title":"Left atrial appendage occlusion","volume":"18","author":"Holmes DR Jr","year":"2023","unstructured":"Holmes DR Jr, Korsholm K, Rod\u00e9s-Cabau J, Saw J, Berti S, Alkhouli MA. Left atrial appendage occlusion. EuroIntervention. 2023, 18:e1038-e1065. 10.4244\/EIJ-D-22-00627","journal-title":"EuroIntervention"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2024.05.016","article-title":"Zero-contrast left atrial appendage closure, a feasible alternative for patients with a high risk of contrast-induced nephropathy: systematic literature review and meta-analysis","author":"Rodriguez JF","year":"2024","unstructured":"Rodriguez JF, Pach\u00f3n-Londo\u00f1o MJ, Areiza LA, Rodriguez WG. Zero-contrast left atrial appendage closure, a feasible alternative for patients with a high risk of contrast-induced nephropathy: systematic literature review and meta-analysis. Heart Rhythm. 2024, 10.1016\/j.hrthm.2024.05.016","journal-title":"Heart Rhythm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30559","article-title":"Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a German multicenter registry","volume":"101","author":"Fink T","year":"2023","unstructured":"Fink T, Paitazoglou C, Bergmann MW, et al.. Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a German multicenter registry. Catheter Cardiovasc Interv. 2023, 101:610-619. 10.1002\/ccd.30559","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.01.003","article-title":"Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation","volume":"207","author":"Kefer J","year":"2016","unstructured":"Kefer J, Tzikas A, Freixa X, et al.. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol. 2016, 207:335-340. 10.1016\/j.ijcard.2016.01.003","journal-title":"Int J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.06.008","article-title":"The association of chronic kidney disease with outcomes following percutaneous left atrial appendage closure","volume":"14","author":"Ahuja KR","year":"2021","unstructured":"Ahuja KR, Ariss RW, Nazir S, Vyas R, Saad AM, Macciocca M, Moukarbel GV. The association of chronic kidney disease with outcomes following percutaneous left atrial appendage closure. JACC Cardiovasc Interv. 2021, 14:1830-1839. 10.1016\/j.jcin.2021.06.008","journal-title":"JACC Cardiovasc Interv"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.04.004","article-title":"Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with Watchman","volume":"12","author":"S\u00f8ndergaard L","year":"2019","unstructured":"S\u00f8ndergaard L, Wong YH, Reddy VY, et al.. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with Watchman. JACC Cardiovasc Interv. 2019, 12:1055-1063. 10.1016\/j.jcin.2019.04.004","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/294636-left-atrial-appendage-closure-a-single-center-experience-in-a-population-with-a-high-prevalence-of-end-stage-renal-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T22:28:22Z","timestamp":1726180102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/294636-left-atrial-appendage-closure-a-single-center-experience-in-a-population-with-a-high-prevalence-of-end-stage-renal-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.69286","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}